A director in translational medicine at a large pharma company speaks about their understanding of the utility of MRD and monitoring. They favor ctDNA monitoring as having more use-cases today, assuming that the assays have high sensitivity and specificity. They work mostly with trials for lung cancer patients, but they expect that other solid tumor cancers will benefit from these technologies in the future, especially if approaches are tumor informed. A strong user of Natera and Foundation Medicine, this stakeholder does not expect to switch vendors in the near future. They hope to see more coverage of these technologies in coming years to help with wider adoptions of testing and note that high prices are a barrier to uptake.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care